FI943564L - Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia - Google Patents

Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia Download PDF

Info

Publication number
FI943564L
FI943564L FI943564A FI943564A FI943564L FI 943564 L FI943564 L FI 943564L FI 943564 A FI943564 A FI 943564A FI 943564 A FI943564 A FI 943564A FI 943564 L FI943564 L FI 943564L
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
granulocyte colony
stimulating activity
Prior art date
Application number
FI943564A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943564A7 (fi
FI943564A0 (fi
Inventor
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI943564A7 publication Critical patent/FI943564A7/fi
Publication of FI943564A0 publication Critical patent/FI943564A0/fi
Publication of FI943564L publication Critical patent/FI943564L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI943564A 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia FI943564L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9201065A FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
PCT/FR1993/000086 WO1993015211A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant

Publications (3)

Publication Number Publication Date
FI943564A7 FI943564A7 (fi) 1994-07-29
FI943564A0 FI943564A0 (fi) 1994-07-29
FI943564L true FI943564L (fi) 1994-07-29

Family

ID=9426191

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943564A FI943564L (fi) 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia

Country Status (8)

Country Link
US (1) US5665863A (show.php)
EP (1) EP0624200A1 (show.php)
JP (1) JPH07503844A (show.php)
CA (1) CA2125979A1 (show.php)
FI (1) FI943564L (show.php)
FR (1) FR2686900B1 (show.php)
NO (1) NO942858L (show.php)
WO (1) WO1993015211A1 (show.php)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
NZ507782A (en) * 1998-04-30 2003-12-19 Tanox Inc G-CSF receptor agonist antibodies and screening method therefor
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU773428B2 (en) * 1998-10-13 2004-05-27 Peptide Biosciences, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
PT1129720E (pt) 2000-02-29 2004-08-31 Pfizer Prod Inc Factor estimulador de colonias de granulocitos estabilizado
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1983055A1 (en) * 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
DK1355942T3 (da) * 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002332041A1 (en) * 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20080108560A1 (en) * 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
EP1670428A4 (en) * 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
AU2005211725B2 (en) * 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
CA2749802C (en) * 2009-01-16 2016-08-23 Teva Pharmaceutical Industries Ltd. New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US9642917B2 (en) 2011-07-25 2017-05-09 Generon (Shanghai) Corporation, Ltd. Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2014147489A2 (en) 2013-03-15 2014-09-25 Teva Pharmaceutical Industries Ltd. Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia in pediatric patients
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CA3183289A1 (en) 2015-09-08 2017-03-16 Jcr Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
JP2017165713A (ja) 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
US10866963B2 (en) 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
FR2649991B2 (fr) * 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
FI901810A7 (fi) * 1989-04-13 1990-10-14 Vascular Laboratory Inc Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3

Also Published As

Publication number Publication date
FI943564A7 (fi) 1994-07-29
JPH07503844A (ja) 1995-04-27
EP0624200A1 (fr) 1994-11-17
WO1993015211A1 (fr) 1993-08-05
NO942858L (no) 1994-08-01
FR2686900B1 (fr) 1995-07-21
CA2125979A1 (fr) 1993-08-05
FR2686900A1 (fr) 1993-08-06
US5665863A (en) 1997-09-09
FI943564A0 (fi) 1994-07-29
NO942858D0 (show.php) 1994-08-01

Similar Documents

Publication Publication Date Title
FI943564L (fi) Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI943565L (fi) Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
FI943563L (fi) Uusia biologisesti aktiivisia polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
NZ218089A (en) 7-piperazinyl, 4-oxoquinolines and pharmaceutical compositions
FI934274A7 (fi) N-sulfonyyli-2-oksi-indolijohdannaiset, niiden valmistus ja niitä sisä ltävät farmaseuttiset koostumukset
IL92518A0 (en) Aminobenzoates,their preparation and pharmaceutical compositions containing them
FI895047A7 (fi) Tienopyridiinit, niiden valmistus, välituoteet ja niitä sisältävät far maseuttiset koostumukset
IT1232677B (it) Composizione farmaceutica contenente ranitidina
FI844289A7 (fi) Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
ZA89792B (en) Pharmaceutical compositions with improved stability
IL71951A0 (en) Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
FI893643A0 (fi) Farmaceutiska kompositioner.
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
DE3579730D1 (de) Eisen-3-hydroxypyron- oder 3-hydroxypyridon-komplexe und diese enthaltende pharmazeutische zusammensetzungen.
FI943645L (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
NZ217123A (en) 7-alpha-cephalosporins, pharmaceutical compositions and intermediate compounds
IL92830A0 (en) Capsaicin derivatives,their preparation and pharmaceutical compositions containing them
DE3674040D1 (de) Pharmazeutische zusammensetzungen.
IT1213453B (it) Composizione farmaceutica.
IT8621393A0 (it) Composizioni farmaceutiche ad azione vasodilatatrice e dantianossica.
IL79469A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
HUT70031A (en) Alfa, omega-diarylalkane derivatives, their preparation and pharmaceutical compositions containing them
IL99009A0 (en) Polypeptides,their preparation and pharmaceutical compositions containing them
NZ217248A (en) Gem-dihalo-1,8-diamino-4-aza-octones and pharmaceutical compositions

Legal Events

Date Code Title Description
FD Application lapsed